Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hansoh Pharmaceutical Group has announced successful results from its Phase III trial of Ameile, an innovative drug designed to treat EGFR-mutated non-small cell lung cancer, in combination with chemotherapy. The trial demonstrated a significant improvement in progression-free survival for patients, marking an important milestone for the company. Detailed results are set to be presented at an upcoming medical conference.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.